Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
AuteursLeboulleux S, Kapiteijn E, Litière S, Schöffski P, Godbert Y, Rodien P, Jarzab B, Salvatore D, Zanetta S, Capdevila J, Bastholt L, De La Fouchardiere C, Lalami Y, Bardet S, Cornélis F, Dedecjus M, Links T, Sents W, Schlumberger M, Locati DL, Newbold K
Treatment of medication-related osteonecrosis of the jaw with cell therapy.
AuteursBouland CL, Javadian R, Gilis S, Yanni A, Le Clercq M, Mestrallet P, Kampouridis S, Bron D, Lalmand M, Vanden Eynden X, Boutremans E, Dequanter D, Loeb I, Philippart P, Lagneaux L, Meuleman N
